CN110441507B - Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof - Google Patents
Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof Download PDFInfo
- Publication number
- CN110441507B CN110441507B CN201910762495.4A CN201910762495A CN110441507B CN 110441507 B CN110441507 B CN 110441507B CN 201910762495 A CN201910762495 A CN 201910762495A CN 110441507 B CN110441507 B CN 110441507B
- Authority
- CN
- China
- Prior art keywords
- cells
- account
- human
- monoclonal antibody
- terminally differentiated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title abstract description 17
- 230000036039 immunity Effects 0.000 title description 2
- 230000036737 immune function Effects 0.000 claims abstract description 71
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims abstract description 12
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims abstract description 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims abstract description 11
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 11
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims abstract description 11
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims abstract description 11
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 11
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims abstract description 10
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims abstract description 10
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims abstract description 10
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims abstract description 10
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims abstract description 10
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims abstract description 10
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims abstract description 10
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims abstract description 10
- 229940088592 immunologic factor Drugs 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 127
- 210000004027 cell Anatomy 0.000 claims description 83
- 210000000822 natural killer cell Anatomy 0.000 claims description 75
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 32
- 201000010260 leiomyoma Diseases 0.000 claims description 24
- 239000012636 effector Substances 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 19
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 14
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims description 12
- 201000007954 uterine fibroid Diseases 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 11
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 10
- 210000003509 immature nk cell Anatomy 0.000 claims description 10
- 239000012073 inactive phase Substances 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 9
- 210000001939 mature NK cell Anatomy 0.000 claims description 9
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 8
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 108700041286 delta Proteins 0.000 claims description 4
- 238000001514 detection method Methods 0.000 abstract description 33
- 239000000367 immunologic factor Substances 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 20
- 239000000439 tumor marker Substances 0.000 description 9
- 201000004458 Myoma Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000010219 correlation analysis Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a reagent combination for detecting the immune function of a patient with hysteromyoma, a kit thereof and a method thereof, and relates to the technical field of biological medicine, in particular to the reagent combination, which comprises a plurality of reagents for detecting a plurality of immune function indexes of the following immune factors: CD3, CD4, CD8, CD45RA, CCR7, CD127, CXCR3, CXCR5, CCR4, CD56, NKG2D, NKP46, γδ, and vδ2. The reagent combination can effectively and accurately detect the immune function of a patient suffering from hysteromyoma, and overcomes the defects of inaccurate detection results and high detection cost in the prior art.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a reagent combination for detecting the immune function of a patient with hysteromyoma, a kit and a method thereof.
Background
The immune function of human immune cells has direct correlation with the occurrence and progress of various diseases, for example, the occurrence and development processes of tumors are the results of long-term down-regulation or inhibition of the functions of human autoimmune cells. Uterine fibroids in women of childbearing age are benign tumors that occur in the reproductive organs and are a common disorder in the female population. However, the occurrence cause of hysteromyoma is not clear at present, and meanwhile, the aspects of curative effect observation, prognosis monitoring and the like in clinical treatment are not fully studied.
Since the human immune system plays a vital role in the occurrence and development of diseases. For example, tumors occur mainly because cells whose body functions are abnormal or mutant cells cannot be recognized by immune cells, are killed, and cause abnormal proliferation of the group of mutant cells, thereby developing tumors.
Although uterine fibroids belong to benign tumors and generally do not affect quality of life and fertility, some patients suffering from uterine fibroids also have adverse consequences, such as infertility, menorrhagia, hemorrhage, etc., thereby affecting the life health of females. Such patients typically track their efficacy and prognosis during clinical treatment by ultrasound imaging or CT imaging.
Currently, there is a lack of methods for detecting prognosis of patients with uterine fibroids that are rapid, accurate and inexpensive.
Disclosure of Invention
The embodiment of the invention provides a reagent combination for detecting the immune function of a hysteromyoma patient, which can effectively and accurately detect the immune function of the hysteromyoma patient and solves the defects of inaccurate detection result and high detection cost in the prior art. The term "myoma patient" refers to a patient who has had myoma and/or a group susceptible to myoma.
Specifically, the reagent combination comprises a plurality of reagents for detecting a plurality of immune function indexes, specifically a plurality of reagents for detecting a plurality of immune function indexes of the following immune factors; the immune factors include: CD3, CD4, CD8, CD45RA, CCR7, CD127, CXCR3, CXCR5, CCR4, CD56, NKG2D, NKP46, γδ, and vδ2. Further, immune factors also include KIR, NKP30, and CD94.
Further, the plurality of immune function indicators include: t cells, helper T cells, killer T cells, biscationic T cells, initializing cd4+ T cells, terminally differentiated cd4+ T cells, central memory cd4+ T cells, effector memory cd4+ T cells, initializing cd8+ T cells, terminally differentiated cd8+ T cells, central memory cd8+ T cells, effector memory cd8+ T cells, inactive phase specific terminally differentiated cd8+ T cells, th2, tfh2, immature NK cells, activated NK cells, virus-infected specific killer NK cells, vδ2+ positive cells, and functional vδ2+ positive cells.
Preferably, the plurality of immune function indicators further comprises: continuously expressing virus-specific terminally differentiated CD8+ T cells, mature NK cells, early function blocking NK cells, conventional killer NK cells;
further preferably, the plurality of immune function indicators further comprises: t cells, th and Tc ratios, γδt cells, vδ1+ positive cells, and (vδ1+/vδ2+) cell ratios.
The invention also provides a method for detecting the immune function of the uterine fibroid patient, which can detect and analyze the crowd infected with the uterine fibroid or the crowd susceptible to the uterine fibroid (healthy crowd) in a low-cost mode, and accurately evaluate the immune function state of the test crowd so that a detected person can take corresponding measures in time, and the detection method is easy to operate and popularize.
Specifically, the method comprises the step of analyzing various immune function indexes by using a flow cytometry by adopting the reagent combination for evaluating the immune function of the hysteromyoma patient. The multiple immune function indexes refer to multiple immune function indexes in the reagent combination, and are not described in detail.
When the measurement results of the various immune function indexes meet the measurement standards, the sample is judged to be healthy people, and the measurement standards of the indexes are as follows:
t cells account for 45.76% -77.45% of lymphocytes; helper T cells account for 40% -67% of T cells; killer T cells account for 31% -58% of T cells; double positive T cells account for 1% -5% of T cells; the initialized CD4+ T cells account for 21.0% -51.6% of the CD4T cells; terminally differentiated CD4+ T cells account for 13.8% -16.8% of CD4T cells; the central memory CD4+ T cells account for 18.2% -49.4% of the CD4T cells; effector memory CD4+ T cells account for 27.6% -55.9% of CD4T cells; initializing 35.4% -53.2% of CD8+ T cells; terminally differentiated cd8+ T cells account for 21.2% -40.3% of CD8T cells; the central memory CD8+ T cells account for 4.8% -6% of the CD8T cells; effector memory cd8+ T cells account for 33.1% -56.3% of CD8T cells; the specific terminally differentiated CD8+ T cells in the inactive phase account for 85.2% -98.8% of the terminally differentiated CD8+ T cells; th2 accounts for 12% -25% of Th cells; tfh2 accounts for 15.3% -23.6% of Tfh cells; immature NK cells account for 5.6% -27.8% of NK cells; activated NK cells account for 25% -53% of NK cells; the specific killing NK cells infected by the virus account for 9.93% -80.85% of the NK cells; v delta 2+ positive cells account for 46.8% -72% of gamma delta T cells; the V delta 2+ positive cells account for 94.6% -99.8% of the V delta 2 gamma delta T cells.
Further, the measurement criteria of the index further include: continuously expressing virus-specific terminally differentiated CD8+ T cells accounting for 6.4% -20% of the terminally differentiated CD8+ T cells; mature NK cells account for 43-82% of NK cells; early function blocking NK cells account for 36.3% -52.7% of NK cells; conventional killer NK cells account for 38.5% -64% of NK cells;
further preferably, the measurement criteria of the index further include: the ratio of Th to Tc is 0.57-2.44; gamma delta T cells account for 0.5 to 8.2 percent of T cells; v delta 1+ positive cells account for 8.2% -24% of gamma delta T cells; the ratio of (vδ1+/vδ2+) is 0.12 to 0.51.
In addition, the invention also provides a kit for detecting the immune function of a patient with hysteromyoma, which comprises a plurality of monoclonal antibodies for detecting various immune function indexes; the monoclonal antibody comprises:
an anti-human CD3 monoclonal antibody, an anti-human CD4 monoclonal antibody, an anti-human CD8 monoclonal antibody, an anti-human CD45RA monoclonal antibody, an anti-human CCR7 monoclonal antibody, an anti-human CD127 monoclonal antibody, an anti-human CXCR3 monoclonal antibody, an anti-human CXCR5 monoclonal antibody, an anti-human CCR4 monoclonal antibody, an anti-human CD56 monoclonal antibody, an anti-human NKG2D monoclonal antibody, an anti-human NKP46 monoclonal antibody, an anti-human γδ monoclonal antibody, an anti-human vδ 2 monoclonal antibody, an anti-human KIR monoclonal antibody, an anti-human NKP30 monoclonal antibody, and an anti-human CD94 monoclonal antibody.
Anti-human CD3 monoclonal antibodies, anti-human CD4 monoclonal antibodies, anti-human CD8 monoclonal antibodies, anti-human CD45RA monoclonal antibodies, anti-human CCR7 monoclonal antibodies, anti-human CD127 monoclonal antibodies, anti-human CXCR3 monoclonal antibodies, anti-human CXCR5 monoclonal antibodies, anti-human CCR4 monoclonal antibodies, anti-human CD56 monoclonal antibodies, anti-human NKG2D monoclonal antibodies, anti-human NKP46 monoclonal antibodies, anti-human γδ monoclonal antibodies, and anti-human vδ 2 monoclonal antibodies.
Preferably, the reagent further comprises: anti-human KIR monoclonal antibodies, anti-human NKP30 monoclonal antibodies, and anti-human CD94 monoclonal antibodies.
The kit can comprehensively reflect the immune function state of women of childbearing age through 28 functional parameters of 17 antibody detection samples, especially patients suffering from uterine fibroids or people susceptible to uterine fibroids, so that women susceptible to uterine fibroids can timely take appropriate measures to keep the health state of the body.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a first test result of an immune function index in embodiment 5 of the present invention;
FIG. 2 is a second test result of the immune function index in embodiment 5 of the present invention;
FIG. 3 is a third test result of the immune function index in the embodiment 5 of the present invention;
FIG. 4 shows a fourth test result of the immune function index in the embodiment 5 of the present invention;
FIG. 5 is a fifth test result of the immune function index in the embodiment 5 of the present invention;
FIG. 6 shows the content of the tumor marker CD125 in the verification example 1 of the present invention;
FIG. 7 shows the content of the tumor marker CD125 and the number of myomas in the sample of verification example 2 according to the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The features and capabilities of the present invention are described in further detail below in connection with the examples.
Example 1
The embodiment provides a reagent combination for detecting the immune function of a patient with hysteromyoma, which comprises the following reagents for detecting various immune function indexes, wherein each reagent respectively and correspondingly comprises any monoclonal antibody; anti-human CD3 monoclonal antibodies, anti-human CD4 monoclonal antibodies, anti-human CD8 monoclonal antibodies, anti-human CD45RA monoclonal antibodies, anti-human CCR7 monoclonal antibodies, anti-human CD127 monoclonal antibodies, anti-human CXCR3 monoclonal antibodies, anti-human CXCR5 monoclonal antibodies, anti-human CCR4 monoclonal antibodies, anti-human CD56 monoclonal antibodies, anti-human NKG2D monoclonal antibodies, anti-human NKP46 monoclonal antibodies, anti-human γδ monoclonal antibodies, and anti-human vδ 2 monoclonal antibodies.
Example 2
The embodiment provides a reagent combination for detecting the immune function of a patient with hysteromyoma, which comprises the following reagents for detecting various immune function indexes, wherein each reagent respectively and correspondingly comprises any monoclonal antibody; anti-human CD3 monoclonal antibodies, anti-human CD4 monoclonal antibodies, anti-human CD8 monoclonal antibodies, anti-human CD45RA monoclonal antibodies, anti-human CCR7 monoclonal antibodies, anti-human CD127 monoclonal antibodies, anti-human CXCR3 monoclonal antibodies, anti-human CXCR5 monoclonal antibodies, anti-human CCR4 monoclonal antibodies, anti-human CD56 monoclonal antibodies, anti-human NKG2D monoclonal antibodies, anti-human NKP46 monoclonal antibodies, anti-human γδ monoclonal antibodies, anti-human vδ 2 monoclonal antibodies, anti-human KIR monoclonal antibodies, anti-human NKP30 monoclonal antibodies, and anti-human CD94 monoclonal antibodies.
Example 3
This example provides a method for detecting immune function in a patient with uterine fibroid, comprising performing a detection assay of a plurality of immune function indicators on a sample by flow cytometry using the reagent combination provided in example 1.
The various immune function indicators include: t cells, helper T cells, killer T cells, biscationic T cells, initializing cd4+ T cells, terminally differentiated cd4+ T cells, central memory cd4+ T cells, effector memory cd4+ T cells, initializing cd8+ T cells, terminally differentiated cd8+ T cells, central memory cd8+ T cells, effector memory cd8+ T cells, inactive phase specific terminally differentiated cd8+ T cells, th2, tfh2, immature NK cells, activated NK cells, virus-infected specific killer NK cells, vδ2+ positive cells, and functional vδ2+ positive cells.
When the measurement result of the immune function index meets the measurement standard, the sample is judged to be healthy people, and the measurement standard of the index is as follows:
t cells account for 45.76% -77.45% of lymphocytes; helper T cells account for 40% -67% of T cells; killer T cells account for 31% -58% of T cells; double positive T cells account for 1% -5% of T cells; the initialized CD4+ T cells account for 21.0% -51.6% of the CD4T cells; terminally differentiated CD4+ T cells account for 13.8% -16.8% of CD4T cells; the central memory CD4+ T cells account for 18.2% -49.4% of the CD4T cells; effector memory CD4+ T cells account for 27.6% -55.9% of CD4T cells; initializing 35.4% -53.2% of CD8+ T cells; terminally differentiated cd8+ T cells account for 21.2% -40.3% of CD8T cells; the central memory CD8+ T cells account for 4.8% -6% of the CD8T cells; effector memory cd8+ T cells account for 33.1% -56.3% of CD8T cells; the specific terminally differentiated CD8+ T cells in the inactive phase account for 85.2% -98.8% of the terminally differentiated CD8+ T cells; th2 accounts for 12% -25% of Th cells; tfh2 accounts for 15.3% -23.6% of Tfh cells; immature NK cells account for 5.6% -27.8% of NK cells; activated NK cells account for 25% -53% of NK cells; the specific killing NK cells infected by the virus account for 9.93% -80.85% of the NK cells; v delta 2+ positive cells account for 46.8% -72% of gamma delta T cells; the V delta 2+ positive cells account for 94.6% -99.8% of the V delta 2 gamma delta T cells.
Example 4
This example provides a method for detecting immune function in a patient with uterine fibroid, comprising performing a detection assay of a plurality of immune function indicators on a sample by flow cytometry using the reagent combination provided in example 2.
The various immune function indicators include: t cells, helper T cells, killer T cells, biscationic T cells, initialization cd4+ T cells, terminally differentiated cd4+ T cells, central memory cd4+ T cells, effector memory cd4+ T cells, initialization cd8+ T cells, terminally differentiated cd8+ T cells, central memory cd8+ T cells, effector memory cd8+ T cells, inactive phase-specific terminally differentiated cd8+ T cells, th2, tfh2, immature NK cells, activated NK cells, virus-infected specific killer NK cells, vδ2+ positive cells, functional vδ2+ positive cells, terminally differentiated cd8+ T cells continuously expressing virus-specific, mature NK cells, early function blocking NK cells, conventional killer NK cells.
When the measurement result of the immune function index meets the measurement standard, the sample is judged to be healthy people, and the measurement standard of the index is as follows:
t cells account for 45.76% -77.45% of lymphocytes; helper T cells account for 40% -67% of T cells; killer T cells account for 31% -58% of T cells; double positive T cells account for 1% -5% of T cells; the initialized CD4+ T cells account for 21.0% -51.6% of the CD4T cells; terminally differentiated CD4+ T cells account for 13.8% -16.8% of CD4T cells; the central memory CD4+ T cells account for 18.2% -49.4% of the CD4T cells; effector memory CD4+ T cells account for 27.6% -55.9% of CD4T cells; initializing 35.4% -53.2% of CD8+ T cells; terminally differentiated cd8+ T cells account for 21.2% -40.3% of CD8T cells; the central memory CD8+ T cells account for 4.8% -6% of the CD8T cells; effector memory cd8+ T cells account for 33.1% -56.3% of CD8T cells; the specific terminally differentiated CD8+ T cells in the inactive phase account for 85.2% -98.8% of the terminally differentiated CD8+ T cells; th2 accounts for 12% -25% of Th cells; tfh2 accounts for 15.3% -23.6% of Tfh cells; immature NK cells account for 5.6% -27.8% of NK cells; activated NK cells account for 25% -53% of NK cells; the specific killing NK cells infected by the virus account for 9.93% -80.85% of the NK cells; v delta 2+ positive cells account for 46.8% -72% of gamma delta T cells; the V delta 2+ positive cells account for 94.6-99.8% of the V delta 2 gamma delta T cells; continuously expressing virus-specific terminally differentiated CD8+ T cells accounting for 6.4% -20% of the terminally differentiated CD8+ T cells; mature NK cells account for 43-82% of NK cells; early function blocking NK cells account for 36.3% -52.7% of NK cells; conventional killer NK cells account for 38.5% -64% of NK cells.
Example 5
This example provides a method for detecting immune function in a patient with uterine fibroid comprising performing a 28 immune function index detection assay on a sample by flow cytometry using the reagent combination provided in example 2.
The various immune function indicators include: t cells, helper T cells, killer T cells, biscationic T cells, initialization cd4+ T cells, terminally differentiated cd4+ T cells, central memory cd4+ T cells, effector memory cd4+ T cells, initialization cd8+ T cells, terminally differentiated cd8+ T cells, central memory cd8+ T cells, effector memory cd8+ T cells, inactive phase-specific terminally differentiated cd8+ T cells, th2, tfh2, immature NK cells, activated NK cells, virus-infected specific killer NK cells, vδ2+ positive cells, functional vδ2+ positive cells, terminally differentiated cd8+ T cells continuously expressing virus-specific, mature NK cells, early function blocking NK cells, conventional killer NK cells, T cells, th and Tc ratios, γδ T cells, vδ1+ positive cells, and (vδ1+/vδ2+) cell ratios.
When the measurement result of the immune function index meets the measurement standard, the sample is judged to be healthy people, and the measurement standard of the index is as follows:
t cells account for 45.76% -77.45% of lymphocytes; helper T cells account for 40% -67% of T cells; killer T cells account for 31% -58% of T cells; double positive T cells account for 1% -5% of T cells; the initialized CD4+ T cells account for 21.0% -51.6% of the CD4T cells; terminally differentiated CD4+ T cells account for 13.8% -16.8% of CD4T cells; the central memory CD4+ T cells account for 18.2% -49.4% of the CD4T cells; effector memory CD4+ T cells account for 27.6% -55.9% of CD4T cells; initializing 35.4% -53.2% of CD8+ T cells; terminally differentiated cd8+ T cells account for 21.2% -40.3% of CD8T cells; the central memory CD8+ T cells account for 4.8% -6% of the CD8T cells; effector memory cd8+ T cells account for 33.1% -56.3% of CD8T cells; the specific terminally differentiated CD8+ T cells in the inactive phase account for 85.2% -98.8% of the terminally differentiated CD8+ T cells; th2 accounts for 12% -25% of Th cells; tfh2 accounts for 15.3% -23.6% of Tfh cells; immature NK cells account for 5.6% -27.8% of NK cells; activated NK cells account for 25% -53% of NK cells; the specific killing NK cells infected by the virus account for 9.93% -80.85% of the NK cells; v delta 2+ positive cells account for 46.8% -72% of gamma delta T cells; the V delta 2+ positive cells account for 94.6-99.8% of the V delta 2 gamma delta T cells; continuously expressing virus-specific terminally differentiated CD8+ T cells accounting for 6.4% -20% of the terminally differentiated CD8+ T cells; mature NK cells account for 43-82% of NK cells; early function blocking NK cells account for 36.3% -52.7% of NK cells; conventional killer NK cells account for 38.5% -64% of NK cells; continuously expressing virus-specific terminally differentiated CD8+ T cells accounting for 6.4% -20% of the terminally differentiated CD8+ T cells; mature NK cells account for 43-82% of NK cells; early function blocking NK cells account for 36.3% -52.7% of NK cells; conventional killer NK cells account for 38.5% -64% of NK cells; the ratio of Th to Tc is 0.57-2.44; gamma delta T cells account for 0.5 to 8.2 percent of T cells; v delta 1+ positive cells account for 8.2% -24% of gamma delta T cells; the ratio of (vδ1+/vδ2+) is 0.12 to 0.51.
For specific information on the method, refer to table 1.
Table 1 details of the method
The method of example 5 was used to test patients with uterine fibroids and healthy individuals, and the test results were shown in fig. 1-5. Specifically, fig. 1 is a first test result diagram of immune function indexes, specifically, fig. 1 a is a naive cd4+ T cell test result, fig. 1 a is a central memory cd4+ T cell test result, fig. 1C is a terminally differentiated effector cd4+ T cell test result, fig. 1D is a regulatory T cell test result, fig. 1E is a Th 2T cell test result, and fig. 1F is a Tfh T cell test result;
FIG. 2 is a second test result of the immune function index in embodiment 5 of the present invention; wherein, G in FIG. 2 is the detection result of Tfh1 type T cells, H in FIG. 2 is the detection result of Tfh2 type T cells, and I in FIG. 2 is the cell ratio of Tfh1/Tfh 2; in FIG. 2, J is a Tfh71 type T cell detection result, K is a central memory type CD8+ T cell detection result in FIG. 2, and L is a terminal differentiation effect type and CD127 high expression CD8+ T cell detection result in FIG. 2;
FIG. 3 is a third test result of the immune function index in the embodiment 5 of the present invention; wherein, in fig. 3, M is the end differentiation effect type and CD127 low expression cd8+ T cell detection result, in fig. 3, N is the Tc17 subtype cd8+ T cell detection result, in fig. 3, O is the total NK cell detection result, in fig. 3, P is the CD56 low expression NK cell detection result, in fig. 3, Q is the CD94 positive KIR negative NK cell detection result, and in fig. 3, R is the NKP30 positive NK cell detection result;
FIG. 4 shows a fourth test result of the immune function index in the embodiment 5 of the present invention; wherein, S in fig. 4 is NK cell detection result positive for NKG 20; t is NK cell detection result positive for NKP46 in FIG. 4; u in FIG. 4 is the total γδ T cell assay result; v in fig. 4 is the vδ1 positive γδ T cell assay result; in FIG. 4, W is the result of V.delta.2 positive gamma.delta.T cell detection; x in FIG. 4 is the cell ratio of V.delta.1/V.delta.2;
FIG. 5 is a fifth test result of the immune function index in the embodiment 5 of the present invention; wherein Y in fig. 5 is NKG2D positive vδ2 subpopulation γδt cell detection results; z in FIG. 5 is the result of PD1 positive detection of γδ T cells from the V.delta.2 subpopulation.
The results in fig. 1-5 show that there was a significant difference between the control and patient groups.
And (3) judging results:
the resins given in table 1 are used to score the extent of variation of individual cell subsets in healthy humans by correlation analysis of various parameters of immune cell function with disease occurrence, progression and efficacy of clinical treatment, based on the apparent degree of the difference of various parameters between patients and normal humans:
remarks: the statistical term "significance" is indicated by a sign. One star indicates that the difference reliability exceeds 95%, and 1 score is recorded; two stars are used for indicating that the reliability of the difference exceeds 99 percent, and the score is 2; three stars represent that the reliability of the difference exceeds 99.9%, and score 3 is recorded;
the scores of the detected parameters are summed to obtain a total score, denoted S, from which the patient is evaluated with reference to the following grading criteria:
s=0 point: normal;
s:0 to 10 portions: is basically normal;
s: 11-24 minutes: the immune function is abnormal, and the recovery needs to be continued;
s: 25-44 minutes: abnormal immune function, close attention, need to condition or therapeutic intervention;
s: 45-54 minutes: serious immune dysfunction, must remain therapeutic intervention;
s is more than or equal to 55 minutes: there is a trend toward further worsening of immune dysfunction, and related treatments such as intensive therapy, replacement of therapeutic regimens, or the use of immune cell therapies to modulate immune function are needed.
Verification example 1
The relationship between the immune function index and tumor diagnosis in example 5 was verified.
The method of example 5 was used to perform regulatory T cell detection analysis on the sample by flow cytometry, and correlate the content of tumor marker CD125 with the content of tumor marker CD125 in the sample, as shown in fig. 6.
As can be seen from fig. 6, the number of regulatory T cells was significantly increased in uterine fibroid patients, and by correlation analysis with the content of tumor marker CD125, it was found that the increase in regulatory T cells was significantly positively correlated with the content of tumor marker CD125 (statistical P value equal to 0.004, indicating extremely significant correlation). It is demonstrated that the content of regulatory T cells can be used as an important index for diagnosis and follow-up observation of hysteromyoma.
Verification example 2
The relationship between the immune function index and tumor diagnosis in example 5 was verified.
By adopting the method of example 5, the sample is subjected to detection analysis of the cell ratio of Tfh1/Tfh2 by a flow cytometer, and the correlation analysis is carried out on the content of the tumor marker CD125 and the myoma number of the sample, wherein the content of the tumor marker CD125 and the myoma number are shown in the figure 7.
As can be seen from fig. 7, the ratio of type I and type II helper follicular T cells (Tfh) was significantly increased in uterine myoma patients, and the correlation analysis was performed on the content of the tumor marker CD125 and the myoma number, and the increase in the cell ratio was found to be significantly positively correlated with CD125 and the myoma number (statistical P values were equal to 0.001 and 0.017, respectively, indicating that the correlation was extremely significant). The ratio of type I and type II helper follicular T cells (Tfh) is also an important indicator for diagnosis and follow-up observation of uterine fibroids and for evaluation of their severity.
By detecting these parameters, a sub-population of cells that are dysfunctional in a patient can assist in clinical diagnosis, treatment, and in particular in assessing the effect of the course of administration on the patient's immune function. For example, if these significantly increased or decreased parameters are returned to normal during treatment, it is indicated that the treatment regimen employed will restore the patient's immune function and have clinical efficacy. Meanwhile, if the treatment is found to be unable to restore the immune function of the patient by detection, the doctor can be prompted to replace the treatment scheme in time. And after the immune function is recovered to be normal, reminding a doctor of stopping the medicine in time.
In summary, an embodiment of the present invention provides a reagent combination for detecting immune functions of a patient with uterine fibroid, where the reagent combination includes a plurality of reagents for detecting a plurality of immune function indicators of immune factors including: CD3, CD4, CD8, CD45RA, CCR7, CD127, CXCR3, CXCR5, CCR4, CD56, NKG2D, NKP46, γδ, and vδ2. The reagent combination can effectively and accurately detect the immune function of a patient suffering from hysteromyoma, and overcomes the defects of inaccurate detection results and high detection cost in the prior art. The reagent combination can effectively and accurately detect the immune function of a patient suffering from hysteromyoma, and overcomes the defects of inaccurate detection results and high detection cost in the prior art.
The invention also provides a method for detecting the immune function of the uterine fibroid patient, which can detect and analyze the crowd infected with the uterine fibroid or the crowd susceptible to the uterine fibroid (healthy crowd) in a low-cost mode, and accurately evaluate the immune function state of the test crowd so that a detected person can take corresponding measures in time, and the detection method is easy to operate and popularize.
In addition, the invention also provides a kit for detecting the immune function of a patient with hysteromyoma, which comprises a plurality of monoclonal antibodies for detecting various immune function indexes; the monoclonal antibodies include anti-human CD3 monoclonal antibody, anti-human CD4 monoclonal antibody, anti-human CD8 monoclonal antibody, anti-human CD45RA monoclonal antibody, anti-human CCR7 monoclonal antibody, anti-human CD127 monoclonal antibody, anti-human CXCR3 monoclonal antibody, anti-human CXCR5 monoclonal antibody, anti-human CCR4 monoclonal antibody, anti-human CD56 monoclonal antibody, anti-human NKG2D monoclonal antibody, anti-human NKP46 monoclonal antibody, anti-human γδ monoclonal antibody, anti-human vδ2 monoclonal antibody, anti-human KIR monoclonal antibody, anti-human NKP30 monoclonal antibody and anti-human CD94 monoclonal antibody. According to the kit, 28 functional parameters of a sample are detected through 17 antibodies, so that the immune function state of women of childbearing age, especially patients suffering from uterine fibroids or people susceptible to uterine fibroids, can be comprehensively reflected, and the women susceptible to uterine fibroids can timely take appropriate measures to keep the health state of the body.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (1)
1. Use of a plurality of reagents for detecting a plurality of immune function indicators of an immune factor in the preparation of a kit for detecting immune function in a patient having uterine fibroid, the immune factor comprising: CD3, CD4, CD8, CD45RA, CCR7, CD127, CXCR3, CXCR5, CCR4, CD56, NKG2D, NKP46, γδ and vδ2, KIR, NKP30 and CD94;
the reagent comprises a plurality of monoclonal antibodies for detecting various immune function indexes; the monoclonal antibody comprises:
an anti-human CD3 monoclonal antibody, an anti-human CD4 monoclonal antibody, an anti-human CD8 monoclonal antibody, an anti-human CD45RA monoclonal antibody, an anti-human CCR7 monoclonal antibody, an anti-human CD127 monoclonal antibody, an anti-human CXCR3 monoclonal antibody, an anti-human CXCR5 monoclonal antibody, an anti-human CCR4 monoclonal antibody, an anti-human CD56 monoclonal antibody, an anti-human NKG2D monoclonal antibody, an anti-human NKP46 monoclonal antibody, an anti-human γδ monoclonal antibody, an anti-human vδ 2 monoclonal antibody, an anti-human KIR monoclonal antibody, an anti-human NKP30 monoclonal antibody, and an anti-human CD94 monoclonal antibody;
the multiple immune function indicators include: t cells, helper T cells, killer T cells, biscationic T cells, initialization cd4+ T cells, terminally differentiated cd4+ T cells, central memory cd4+ T cells, effector memory cd4+ T cells, initialization cd8+ T cells, terminally differentiated cd8+ T cells, central memory cd8+ T cells, effector memory cd8+ T cells, inactive phase-specific terminally differentiated cd8+ T cells, th2, tfh2, immature NK cells, activated NK cells, virus-infected specific killer NK cells, vδ2+ positive cells and functional vδ2+ positive cells, terminally differentiated cd8+ NK cells continuously expressing virus specificity, mature NK cells, early function blocking NK cells, conventional killer NK cells, th and Tc ratios, γδt cells, vδ1+ positive cells and (vδ1+/vδ2+) cell ratios;
when the measurement result of the immune function index meets the measurement standard, the sample is judged to be healthy people, and the measurement standard of the index is as follows:
t cells account for 45.76% -77.45% of lymphocytes; helper T cells account for 40% -67% of T cells; the killer T cells account for 31% -58% of the T cells; the double positive T cells account for 1% -5% of the T cells; the initialized CD4+ T cells account for 21.0% -51.6% of the CD4T cells; terminally differentiated CD4+ T cells account for 13.8% -16.8% of CD4T cells; the central memory CD4+ T cells account for 18.2% -49.4% of the CD4T cells; effector memory CD4+ T cells account for 27.6% -55.9% of CD4T cells; initializing 35.4% -53.2% of CD8+ T cells; terminally differentiated CD8+ T cells account for 21.2% -40.3% of CD8T cells; the central memory CD8+ T cells account for 4.8% -6% of the CD8T cells; effector memory CD8+ T cells account for 33.1% -56.3% of CD8T cells; the specific terminally differentiated CD8+ T cells in the inactive phase account for 85.2% -98.8% of the terminally differentiated CD8+ T cells; th2 accounts for 12% -25% of Th cells; tfh2 accounts for 15.3% -23.6% of Tfh cells; immature NK cells account for 5.6% -27.8% of NK cells; activated NK cells account for 25% -53% of NK cells; the specific killer NK cells infected by the viruses account for 9.93% -80.85% of the NK cells; v delta 2+ positive cells account for 46.8% -72% of gamma delta T cells; the V delta 2+ positive cells account for 94.6% -99.8% of the V delta 2 gamma delta T cells;
the measurement criteria of the index further include: continuously expressing 6.4% -20% of terminally differentiated CD8+ T cells with virus specificity; mature NK cells account for 43-82% of NK cells; early function blocking NK cells account for 36.3% -52.7% of NK cells; conventional killer NK cells account for 38.5% -64% of NK cells;
the measurement criteria of the index further include: the ratio of Th to Tc is 0.57-2.44; gamma delta T cells account for 0.5% -8.2% of T cells; v delta 1+ positive cells account for 8.2% -24% of gamma delta T cells; the ratio of (V delta 1 < + >/V delta 2 < + >) is 0.12-0.51.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910762495.4A CN110441507B (en) | 2019-08-16 | 2019-08-16 | Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910762495.4A CN110441507B (en) | 2019-08-16 | 2019-08-16 | Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110441507A CN110441507A (en) | 2019-11-12 |
| CN110441507B true CN110441507B (en) | 2023-06-02 |
Family
ID=68436204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910762495.4A Active CN110441507B (en) | 2019-08-16 | 2019-08-16 | Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110441507B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111579779B (en) * | 2020-05-09 | 2022-12-23 | 中山大学附属第一医院 | Marker for evaluating immune cell function of hepatitis B patient and application thereof |
| CN113848169B (en) * | 2021-11-30 | 2022-03-04 | 广州普锐生物科技有限公司 | Healthy human immune cell activity evaluation and analysis method based on PD-1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109254147A (en) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | Human peripheral blood immune cell function fully assesses kit and appraisal procedure |
| CN109406775A (en) * | 2018-10-12 | 2019-03-01 | 东莞市暨科生物科技有限公司 | Autoimmune disease patient's immune function assesses kit and appraisal procedure |
| CN109270265A (en) * | 2018-10-12 | 2019-01-25 | 东莞暨南大学研究院 | The lethal immune cell function assessment kit of human peripheral blood and appraisal procedure |
| CN109212215A (en) * | 2018-10-12 | 2019-01-15 | 东莞市暨科生物科技有限公司 | Tumor patient immune cell function assesses kit and appraisal procedure |
-
2019
- 2019-08-16 CN CN201910762495.4A patent/CN110441507B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110441507A (en) | 2019-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qualai et al. | Expression of CD11c is associated with unconventional activated T cell subsets with high migratory potential | |
| Zamecki et al. | HLA typing in uveitis: use and misuse | |
| Fitch et al. | Emergency department management of meningitis and encephalitis | |
| CN110441507B (en) | Reagent combination for detecting immunity of hysteromyoma patient, kit and method thereof | |
| US10634687B2 (en) | Serum biomarker screen for the diagnosis of clinical and preclinical alzheimer's disease | |
| Sherman et al. | CD4+ T cell enumeration in HIV infection with limited resources | |
| JP6276252B2 (en) | Cell markers for diagnosis of Alzheimer's disease and cell markers of Alzheimer's disease progression | |
| Fahmi et al. | Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis | |
| Ayvaz et al. | The incidence of postpartum depression in Trabzon province and the risk factors during gestation | |
| Kalsdorf et al. | Relationship between chemokine receptor expression, chemokine levels and HIV‐1 replication in the lungs of persons exposed to M ycobacterium tuberculosis | |
| Tang et al. | Establishing immune scoring model based on combination of the number, function, and phenotype of lymphocytes | |
| Long et al. | Recovery of CD226-TIGIT+ FoxP3+ and CD226-TIGIT-FoxP3+ regulatory T cells contributes to clinical remission from active stage in ulcerative colitis patients | |
| RU2583939C1 (en) | Method for laboratory diagnosis of stages of hepatic fibrosis in chronic viral hepatitis c | |
| Ravi et al. | Changes in the Vα7. 2+ CD161++ MAIT cell compartment in early pregnancy are associated with preterm birth in HIV‐positive women | |
| Tseng et al. | Increased incidence of amyotrophic lateral sclerosis in polymyositis: a nationwide cohort study | |
| CN110456057A (en) | Detect the application and recurrent miscarriage detection kit and method of the reagent of immune function | |
| EP3074770A1 (en) | Immune monitoring to predict and prevent infection | |
| Abdolsamadi et al. | epidemiology of pemphigus in Tehran, Iran: a 20-year retrospective study | |
| CN112557283A (en) | Diagnosis and treatment immune marker for recurrent pregnancy loss diseases and application thereof | |
| CN111579779B (en) | Marker for evaluating immune cell function of hepatitis B patient and application thereof | |
| CN115684570B (en) | Infectious disease detection device, apparatus, system, medium, and program product | |
| JP7538910B2 (en) | Method for detecting the effectiveness of immunity and medical use of lymphocytes or natural killer cells | |
| CN114740196B (en) | Marker and application thereof in preparation of product for evaluating organism immune function | |
| Phetsouphanh et al. | Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection | |
| US20220221462A1 (en) | Marker for diagnosing colorectal cancer and method for providing information required for diagnosis of colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |